|
|
[DEM] Same as MCI
|
[DEM] Same as MCI
|
|
|
[MCI] Any significant neurologic disease other than suspected Alzheimer’s disease, such as Parkinson’s disease (Parkinsonian symptoms complicating MCI
|
[MCI] Any significant neurologic disease other than suspected Alzheimer’s disease, such as Parkinson’s disease (Parkinsonian symptoms complicating MCI
|
|
|
AD are acceptable), vascular cognitive impairment dementia (multiple lacunes less than
|
AD are acceptable), vascular cognitive impairment dementia (multiple lacunes less than
|
|
|
attention deficit disorder.
|
attention deficit disorder.
|
|
|
behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
|
behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
|
|
|
equal to 1.5 cm and
|
equal to 1.5 cm and
|
|
|
extensive white matter disease are allowed.
|
extensive white matter disease are allowed.
|
|
|
history of significant head trauma followed by persistent neurologic defaults
|
history of significant head trauma followed by persistent neurologic defaults
|
|
|
known structural brain abnormalities
|
known structural brain abnormalities
|
|
|
known structural brain abnormalities.
|
known structural brain abnormalities.
|
|
|
newpt1
|
1. [CN] Any significant neurologic disease, such as Parkinson’s disease, vascular cognitive impairment/dementia, Huntington’s disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis
|
|
|
newpt10
|
9. Clinically significant abnormalities in B12
|
|
|
newpt11
|
10. Residence in a skilled nursing facility.
|
|
|
newpt12
|
11. Current use of specific psychoactive medications (e.g. certain antidepressants, neuroleptics, chronic anxiolytics
|
|
|
newpt13
|
12. Current use of any other exclusionary medications.
|
|
|
newpt14
|
13. Investigational agents are prohibited for five half-lives
|
|
|
newpt15
|
14. Participation in clinical studies involving neuropsychological measures being collected more than once time per year.
|
|
|
newpt16
|
15. Female that is pregnant, lactating
|
|
|
newpt17
|
16. Flexibility can be made to all criteria for those with at least 8 years in a low socio-economic status (SES) neighborhood
|
|
|
newpt2
|
1. Screening/Baseline MRI brain scan with evidence of infection
|
|
|
newpt3
|
2. Screening/Baseline MRI brain scan with evidence of large structural abnormalities that would corrupt image analytical pipelines –e.g. large hemispheric infarcts, large areas of encephalomalacia, large arachnoid cysts.
|
|
|
newpt4
|
3. Unable to complete MRIs for any reason (e.g. pacemaker
|
|
|
newpt5
|
4. Current major depression, bipolar disorder as described in DMS-IV within the past 1 year. Psychotic features, agitation
|
|
|
newpt6
|
5. Currently treated with medication for obsessive-compulsive disorder
|
|
|
newpt7
|
6. History of schizophrenia (DSM-5 criteria).
|
|
|
newpt8
|
7. History of alcohol
|
|
|
newpt9
|
8. Any significant systemic illness
|
|
|
of childbearing potential.
|
of childbearing potential.
|
|
|
one month, whichever time period is longer, prior to entry and for the duration of the trial.
|
one month, whichever time period is longer, prior to entry and for the duration of the trial.
|
|
|
or extensive white matter changes are acceptable), Huntington’s disease, normal pressure hydrocephalus, brain tumor (clinically insignificant meningioma acceptable), progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis
|
or extensive white matter changes are acceptable), Huntington’s disease, normal pressure hydrocephalus, brain tumor (clinically insignificant meningioma acceptable), progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis
|
|
|
other clinically significant focal lesions. Participants with cortical strokes, not large enough to distort anatomy, multiple lacunar infarctions
|
other clinically significant focal lesions. Participants with cortical strokes, not large enough to distort anatomy, multiple lacunar infarctions
|
|
|
other implanted metal devices, severe claustrophobia, anxiety which prevents MRI scans, too large to fit, etc.).
|
other implanted metal devices, severe claustrophobia, anxiety which prevents MRI scans, too large to fit, etc.).
|
|
|
sedative hypnotics, etc.), at the discretion of the clinician.
|
sedative hypnotics, etc.), at the discretion of the clinician.
|
|
|
substance disorder within the past 2 years (DSM-5 criteria).
|
substance disorder within the past 2 years (DSM-5 criteria).
|
|
|
thyroid function tests that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.
|
thyroid function tests that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.
|
|
|
unstable medical condition which could lead to difficulty complying with the protocol.
|
unstable medical condition which could lead to difficulty complying with the protocol.
|